Dianthus Therapeutics Net Income
| DNTH Stock | 47.40 0.08 0.17% |
As of the 15th of February 2026, Dianthus Therapeutics shows the Downside Deviation of 2.98, mean deviation of 2.58, and Semi Deviation of 2.6. Dianthus Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Dianthus Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Dianthus Therapeutics' valuation are provided below:Dianthus Therapeutics does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Is there potential for Biotechnology market expansion? Will Dianthus introduce new products? Factors like these will boost the valuation of Dianthus Therapeutics. Projected growth potential of Dianthus fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Dianthus Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Dianthus Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Dianthus Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Dianthus Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Dianthus Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Dianthus Therapeutics.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Dianthus Therapeutics on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Dianthus Therapeutics or generate 0.0% return on investment in Dianthus Therapeutics over 90 days. Dianthus Therapeutics is related to or competes with Enliven Therapeutics, Taysha Gene, Sana Biotechnology, ATAI Life, Nektar Therapeutics, AnaptysBio, and Oculis Holding. More
Dianthus Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Dianthus Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Dianthus Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.98 | |||
| Information Ratio | 0.058 | |||
| Maximum Drawdown | 22.93 | |||
| Value At Risk | (4.89) | |||
| Potential Upside | 5.67 |
Dianthus Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Dianthus Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Dianthus Therapeutics' standard deviation. In reality, there are many statistical measures that can use Dianthus Therapeutics historical prices to predict the future Dianthus Therapeutics' volatility.| Risk Adjusted Performance | 0.0696 | |||
| Jensen Alpha | 0.2639 | |||
| Total Risk Alpha | (0) | |||
| Sortino Ratio | 0.0734 | |||
| Treynor Ratio | 1.14 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Dianthus Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Dianthus Therapeutics February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0696 | |||
| Market Risk Adjusted Performance | 1.15 | |||
| Mean Deviation | 2.58 | |||
| Semi Deviation | 2.6 | |||
| Downside Deviation | 2.98 | |||
| Coefficient Of Variation | 1306.09 | |||
| Standard Deviation | 3.77 | |||
| Variance | 14.2 | |||
| Information Ratio | 0.058 | |||
| Jensen Alpha | 0.2639 | |||
| Total Risk Alpha | (0) | |||
| Sortino Ratio | 0.0734 | |||
| Treynor Ratio | 1.14 | |||
| Maximum Drawdown | 22.93 | |||
| Value At Risk | (4.89) | |||
| Potential Upside | 5.67 | |||
| Downside Variance | 8.86 | |||
| Semi Variance | 6.75 | |||
| Expected Short fall | (3.22) | |||
| Skewness | 1.12 | |||
| Kurtosis | 3.27 |
Dianthus Therapeutics Backtested Returns
Dianthus Therapeutics appears to be very steady, given 3 months investment horizon. Dianthus Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0766, which denotes the company had a 0.0766 % return per unit of standard deviation over the last 3 months. We have found twenty-nine technical indicators for Dianthus Therapeutics, which you can use to evaluate the volatility of the firm. Please utilize Dianthus Therapeutics' Semi Deviation of 2.6, downside deviation of 2.98, and Mean Deviation of 2.58 to check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Dianthus Therapeutics holds a performance score of 6. The firm shows a Beta (market volatility) of 0.24, which means not very significant fluctuations relative to the market. As returns on the market increase, Dianthus Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Dianthus Therapeutics is expected to be smaller as well. Please check Dianthus Therapeutics' coefficient of variation, semi variance, price action indicator, as well as the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Dianthus Therapeutics' price patterns will revert.
Auto-correlation | 0.25 |
Poor predictability
Dianthus Therapeutics has poor predictability. Overlapping area represents the amount of predictability between Dianthus Therapeutics time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Dianthus Therapeutics price movement. The serial correlation of 0.25 indicates that over 25.0% of current Dianthus Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.25 | |
| Spearman Rank Test | 0.09 | |
| Residual Average | 0.0 | |
| Price Variance | 29.55 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Dianthus Therapeutics reported net income of (84.97 Million). This is 124.9% lower than that of the Biotechnology sector and 221.31% lower than that of the Health Care industry. The net income for all United States stocks is 114.88% higher than that of the company.
Dianthus Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dianthus Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dianthus Therapeutics could also be used in its relative valuation, which is a method of valuing Dianthus Therapeutics by comparing valuation metrics of similar companies.Dianthus Therapeutics is currently under evaluation in net income category among its peers.
Dianthus Fundamentals
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.19 | ||||
| Operating Margin | (101.74) % | ||||
| Current Valuation | 1.65 B | ||||
| Shares Outstanding | 43.22 M | ||||
| Shares Owned By Insiders | 3.30 % | ||||
| Shares Owned By Institutions | 96.70 % | ||||
| Number Of Shares Shorted | 8.3 M | ||||
| Price To Book | 3.75 X | ||||
| Price To Sales | 665.62 X | ||||
| Revenue | 6.24 M | ||||
| Gross Profit | 3.08 M | ||||
| EBITDA | (101.45 M) | ||||
| Net Income | (84.97 M) | ||||
| Total Debt | 1.49 M | ||||
| Book Value Per Share | 12.75 X | ||||
| Cash Flow From Operations | (78.18 M) | ||||
| Short Ratio | 9.24 X | ||||
| Earnings Per Share | (3.50) X | ||||
| Target Price | 73.0 | ||||
| Number Of Employees | 78 | ||||
| Beta | 1.23 | ||||
| Market Capitalization | 2.05 B | ||||
| Total Asset | 374.01 M | ||||
| Retained Earnings | (174.39 M) | ||||
| Working Capital | 262.45 M | ||||
| Net Asset | 374.01 M |
About Dianthus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dianthus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dianthus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dianthus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is there potential for Biotechnology market expansion? Will Dianthus introduce new products? Factors like these will boost the valuation of Dianthus Therapeutics. Projected growth potential of Dianthus fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Dianthus Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Dianthus Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Dianthus Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.